In addition to lowering its price target from $105 to $64 to market perform, BMO lowered its rating on Novo Nordisk’s shares ...

Amy Schumer has provided fans with a comical update on her weight loss journey. The I Feel Pretty star said she tried Ozempic ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Weight-loss drugs are being doled out within minutes in telehealth consults to patients, triggering warnings from health ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the ...

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...